Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

The Lancet Oncology

Topics

Computer Science

Cancer Oncology

Medicine

Internal Medicine

Pulmonary And Respiratory Medicine

Show all topics

DOI

10.1016/s1470-2045(15)00188-6